Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Over a week ago
Jun 11, 7:59 AM
May 12, 7:16 AM
Mar 25, 7:24 AM
Feb 27, 5:23 AM
Feb 26, 7:01 AM
Feb 23, 12:01 PM
Feb 23, 7:03 AM
Jan 14, 7:03 AM
Dec 17, 5:54 AM
Dec 2, 5:39 AM
Nov 21, 4:09 PM
Nov 6, 7:20 AM
Nov 6, 7:20 AM
Oct 16, 7:16 AM
Sep 23, 6:14 AM
Sep 22, 7:14 AM
Sep 21, 10:53 AM
Sep 16, 4:46 PM
Sep 16, 4:16 PM
Competitive Advantages
Proprietary DEGRONIMID™ Platform: C4T possesses a leading, proprietary platform designed for the discovery and development of targeted protein degraders, enabling precise elimination of disease-causing proteins.
Broad E3 Ligase Engagement: The company has demonstrated expertise in leveraging multiple E3 ubiquitin ligases (e.g., CRBN, VHL), expanding the universe of potentially degradable targets and therapeutic opportunities.
Advancing Clinical Pipeline: C4T maintains a robust pipeline with multiple clinical-stage and preclinical programs, both wholly-owned and partnered, targeting various difficult-to-treat cancers.
Risks
Clinical Trial Failures Risk: The company's drug candidates may not achieve positive results in ongoing or future clinical trials, leading to delayed development or complete termination.
Regulatory Approval Uncertainty Risk: Even with positive trial data, the company's drug candidates may not receive necessary regulatory approvals from agencies like the FDA, preventing commercialization.
Intense Competition Risk: C4 Therapeutics operates in a highly competitive biopharmaceutical market, especially in oncology and targeted protein degradation, which could impact market share and profitability.